See how single-cell spatial data is de-risking target discovery and accelerating oncology drug development.
How does single-cell spatial transcriptomics fit into real-world drug development pipelines? Hear from a precision oncology CRO and a cancer research foundation studying "exceptional survivors", patients who outlive some of the most aggressive cancers by years, about how Xenium is helping uncover what sets their biology apart, and how the same platform supports lead compound profiling.
Why watch this video?
- See how researchers are uncovering what sets rare, long-term cancer survivors apart biologically, insight that could point toward new therapeutic angles
- Learn how bringing in the right expertise can put high-resolution spatial data to work for target discovery, mechanism-of-action (MOA) studies, and biomarker identification without slowing your program down
- Understand how this approach can de-risk decisions and accelerate a therapeutic pipeline, even when working across large, precious FFPE tumor cohorts
- Hear two complementary points of view, from the team generating the data and the team turning it into biological insight
